Abstract: Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as breast cancer.

Abstract: Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as breast cancer.

Abstract: Systems, devices and automated processes reduce the effects of unwanted interruption during video encoding by reserving header space at the outset of video encoding. This reserved space can be progressively filled on any periodic or other basis as encoding continues so that a recent header is always available. If an interruption occurs, only the video content encoded after the last header write will be lost, thereby greatly reducing the effects of the interruption.

Abstract: Compounds of Formula (I) are estrogen receptor alpha modulators, where the variables in Formula (I) are described in the disclosure. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions that are estrogen receptor alpha dependent and/or estrogen receptor alpha mediated, including conditions characterized by excessive cellular proliferation, such as breast cancer.

Abstract: Compounds of Formula (I) are estrogen receptor alpha modulators, where the variables in Formula (I) are described in the disclosure. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions that are estrogen receptor alpha dependent and/or estrogen receptor alpha mediated, including conditions characterized by excessive cellular proliferation, such as breast cancer.

Abstract: Compounds of Formula (I) are estrogen receptor alpha modulators, where the variables in Formula (I) are described in the disclosure. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions that are estrogen receptor alpha dependent and/or estrogen receptor alpha mediated, including conditions characterized by excessive cellular proliferation, such as breast cancer.

Abstract: A system includes a computer that is programmed to receive one or more media streams, each from a respective one of a one or more media capture devices, and to receive, from a client device, for each of the one or more media streams, state data including at least one of an active and a potential state of the media stream. The computer is further programmed to disconnect from the client device, and then, upon reconnecting to the client device, to provide at least one of the media streams and the state data to the client device.

Abstract: Embodiments of the present disclosure include a system for coupling objects in a wellbore includes a unidirectional valve having a body. The body includes two or more body lugs extending radially outward, each body lug of the two or more body lugs extending at least a portion of a circumferential distance of the body. The system also includes a tubing hanger having a bore that receives the unidirectional valve. The bore includes an axial restraint system that receives the two or more body lugs and blocks axial movement of the unidirectional valve in a first position and enables axial movement of the unidirectional valve in a section position, the unidirectional valve being non-threadingly coupled to the tubing hanger.

Abstract: Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as breast cancer.

Abstract: Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as breast cancer.

Abstract: Compounds of Formula (I) are estrogen receptor alpha modulators, where the variables in Formula (I) are described in the disclosure. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions that are estrogen receptor alpha dependent and/or estrogen receptor alpha mediated, including conditions characterized by excessive cellular proliferation, such as breast cancer.

Abstract: A system includes a computer that is programmed to receive one or more media streams, each from a respective one of a one or more media capture devices, and to receive, from a client device, for each of the one or more media streams, state data including at least one of an active and a potential state of the media stream. The computer is further programmed to disconnect from the client device, and then, upon reconnecting to the client device, to provide at least one of the media streams and the state data to the client device.

Abstract: Various arrangements for debugging a hung thread of a software application are presented. A thread monitor module may be executed that monitors for any hung threads within a plurality of executing threads. A monitoring initialization message may be received that initiates thread monitoring of a thread. In response to the monitoring initialization message, tracking of the thread may be commenced by determining whether an update message for the thread has been received within an amount of time allotted for the update message to be sent. If the update message is not received, the thread may be identified as hung. Debugging information generated in response to identifying the hung thread may be used for creating an improved version of the software application that prevents the hang.

Abstract: Uses and methods that include an effective amount of Compound (A), or a pharmaceutically acceptable salt thereof, are described herein for treating breast cancer in a subject in need thereof, wherein the breast cancer has at least one point mutation within the Estrogen Receptor 1 (ESR1) that encodes Estrogen receptor alpha (ER?).

Abstract: Embodiments of the present disclosure include a system for installing a slip hanger assembly in a wellbore with a slip bowl comprising an aperture extending from an outer diameter of the slip bowl. The system also includes a slip coupled to the slip bowl, the slip comprising teeth on an inner face and a slot for receiving a shear pin extending through the aperture. The system further includes a running tool coupled to the slip bowl. The system includes a housing coupled to the running tool, the housing including a cylinder for receiving a reciprocating piston, the piston being movable between a first position and a second position, wherein the slip is in stored position while the piston is in the first position and an engaged position when the piston is in the second position.

Abstract: Compounds of Formula (I) are estrogen receptor alpha modulators, where the variables in Formula (I) are described in the disclosure. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions that are estrogen receptor alpha dependent and/or estrogen receptor alpha mediated, including conditions characterized by excessive cellular proliferation, such as breast cancer.

Abstract: Compounds of Formula (I) are estrogen receptor alpha modulators, where the variables in Formula (I) are described in the disclosure. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions that are estrogen receptor alpha dependent and/or estrogen receptor alpha mediated, including conditions characterized by excessive cellular proliferation, such as breast cancer.

Abstract: Compounds of Formula (I) are estrogen receptor alpha modulators, where the variables in Formula (I) are described in the disclosure. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions that are estrogen receptor alpha dependent and/or estrogen receptor alpha mediated, including conditions characterized by excessive cellular proliferation, such as breast cancer.

Abstract: Embodiments of the present disclosure include a multi-inlet fracturing head (MIFH) having a first inlet channel extending through a body of the MIFH, the first inlet channel being substantially perpendicular to an axis of the MIFH and directing fluid into a first flow passage of the MIFH. The MIFH also includes a second inlet channel extending through the body of the MIFH, the second inlet channel being at an angle relative to the axis and directing fluid into the first flow passage of the MIFH.

Abstract: A device includes a failsafe circuit having a supply node configured to couple to a supply voltage source, a pad node configured to couple to an input/output (I/O) pin, and a bulk node configured to couple to a bulk of a transistor coupled to the I/O pin. The failsafe circuit is configured to assert a failsafe indicator signal when the supply node voltage falls below the pad node voltage by a threshold voltage, and couple the higher of the supply node voltage and the pad node voltage to the bulk node. The device also includes a pull-down stack coupled to the failsafe circuit and to a ground node, and a sub-circuit configured to turn off the pull-down stack in response to the supply node discharging to the threshold voltage below the pad node voltage.